

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 February 2009 (05.02.2009)

PCT

(10) International Publication Number
WO 2009/016072 A3

(51) International Patent Classification:

A61K 45/06 (2006.01) A61K 31/706 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2008/059621

(22) International Filing Date: 23 July 2008 (23.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

07113731.9 2 August 2007 (02.08.2007) EP

(71) Applicant (for all designated States except US): **NERVIANO MEDICAL SCIENCES S.r.l.** [IT/IT]; Viale Pasteur, 10, I-20014 Nerviano (MI) (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GERONI, Maria Cristina** [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). **VALOTA, Olga** [IT/IT]; Via Nazario Sauro, 99, I-20025 Legnano (MI) (IT). **BALLINARI, Dario** [IT/IT]; Via Carlo Jannozzi, 8, I-20097 San Donato Milanese (MI) (IT). **MARSIGLIO, Aurelio** [IT/IT]; Via Dante Alighieri, 33, I-21047 Saronno (VA) (IT).(74) Common Representative: **NERVIANO MEDICAL SCIENCES S.r.l.**; Viale Pasteur, 10, I-20014 Nerviano (MI) (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
22 May 2009

(54) Title: A MORPHOLINYL ANTHRACYCLINE DERIVATIVE COMBINED WITH PROTEIN KINASE INHIBITORS



(I)

(57) Abstract: The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/059621

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K45/06 A61P35/00 A61K31/706

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2006/120557 A (PFIZER [US]; BAUM CHARLES MICHAEL [US]) 16 November 2006 (2006-11-16) page 50, line 3 - page 51, line 27	1-11
Y	RICHLI H ET AL: "Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors." ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO MAY 2006, vol. 17, no. 5, May 2006 (2006-05), pages 866-873, XP002520236 ISSN: 0923-7534 abstract	1-11

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

20 March 2009

Date of mailing of the international search report

06/04/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Escobar Blasco, P

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/059621

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SESSA C ET AL: "Ongoing phase I and II studies of novel anthracyclines" CARDIOVASCULAR TOXICOLOGY 200706 US, vol. 7, no. 2, June 2007 (2007-06), pages 75-79, XP002520237 ISSN: 1530-7905 page 75, left-hand column, paragraph 1 page 77, left-hand column, paragraph 3 - right-hand column, paragraph 1	1-11
Y	HUETHER A ET AL: "Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics" JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 43, no. 4, 1 October 2005 (2005-10-01), pages 661-669, XP025293954 ISSN: 0168-8278 [retrieved on 2005-10-01] page 667, left-hand column, paragraph 4; figure 5	1-3,5-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/059621

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006120557 A	16-11-2006	AR 057295 A1	28-11-2007
		AU 2006245421 A1	16-11-2006
		CA 2603445 A1	16-11-2006
		EP 1885355 A1	13-02-2008
		JP 2006316060 A	24-11-2006
		KR 20070119745 A	20-12-2007
		US 2008193448 A1	14-08-2008